hrp0086p2-p663 | Growth P2 | ESPE2016

A Case of GH Deficiency in a Female with 3M Syndrome

Bortone Barbara , Scalini Perla , de Martino Maurizio , Giglio Sabrina , Lapi Elisabetta , della Monica Matteo , Stagi Stefano

Background: 3-M syndrome is an autosomal recessive primordial growth disorder characterized by severe prenatal and postnatal growth retardation, normal mental development, unusual facial features and skeletal abnormalities. Mutations in the CUL7, OBSL1 and CCDC8 genes are responsible for this syndrome. In literature a modest response to GH treatment in 3M children is reported without a significant improvement in the final height, suggesting a picture...

hrp0086p2-p767 | Pituitary and Neuroendocrinology P2 | ESPE2016

Congenital Hypopituitarism in a Patient with 18p- Syndrome

Bolmasova Anna , Melikian Maria , Degtyareva Anna

Background: 18p- syndrome is very rare (1:50000 live-born infants). Hypopituitarism as part of the syndrome is found in 13% of cases. Here we present a case of congenital hypopituitarism in a girl with 18p- syndrome.Objective and hypotheses: Description of a rare clinical case of congenital hypopituitarism as a feature of 18p- syndrome.Method: Hormonal and biochemical blood tests, MRI, karyotyping, echocardiogram, specialistsÂ’...

hrp0082p3-d2-853 | Growth (3) | ESPE2014

Switching From the Original to the Biosimilar Recombinant Human GH – Omnitrope®: an Experience of a Single Paediatric Centre in Spain

Gila Ana Gomez , Garcia Margarida Palla

Introduction: In 2009/2010 Hospital Virgen del Rocío, Seville, Spain changed the treatment of patients with GH deficiency (GHD) from various original recombinant human GH (rhGH) to a biosimilar rhGh (Omnitrope®, Sandoz).Objective: To evaluate the consequences on growth parameters of switching treatment, from original rhGHs to Omnitrope® in children with GHD, in a window period of 36 months.Metho...

hrp0084fc5.2 | Endocrine Oncology/Turner | ESPE2015

MEN1 Syndrome Because of Combined Germline and Somatic Mosaicism, with Important Consequences for Relatives

Kempers Marlies , Stikkelbroeck Nike , Mensenkamp Arjen , Pfundt Rolph , van der Luijt Rob , Timmers Henri , Claahsen Hedi , Hoogerbrugge Nicoline , Hermus Ad

Background: Multiple endocrine neoplasia type I (MEN1) is characterized by the combined occurrence of tumours in several endocrine tissues such as parathyroid tumours, pituitary tumours (usually prolactinomas) and pancreatic neuroendocrine tumours. MEN1 is an autosomal dominant disorder caused by germline mutations in the tumour suppressor gene MEN1. First-degree relatives of a germline MEN1 mutation carrier have a 50% risk of the mutation. Intensive surveillance of g...

hrp0084p2-202 | Adrenals | ESPE2015

Autoimmune Polyglandular Syndrome Type 1 in Russia: Clinical Experience in 112 Patients

Orlova Elizaveta , Sozaeva Leila , Kareva Maria , Oftedal Bergithe E , Breivik Lars , Knappskog Per M , Zakharova Ekaterina , Husebye Eystein S , Peterkova Valentina

Background: Autoimmune polyglandular syndrome type 1 (APS-1) is a rare disease associated with mutations in the autoimmune regulator (AIRE) gene and characterized by mucocutaneous candidiasis (CMC), hypoparathyroidism (HP) and primary adrenal insufficiency (AI). Two of these three components are required for diagnosis.Objective and hypotheses: To describe Russian patients in terms of clinical, genetic, and immunological parameters....

hrp0084p2-383 | Fat | ESPE2015

Tryptophan Supplementation as Conjunctive Therapy to Life Style Changes in Obese Adolescents

Jaramillo Adriana , Calderon Caterina , Llobet Marina , Sole Laura , Suarez-Ortega Larisa , Lerin Carles , Ramon-Krauel Marta

Background: The correlation between obesity and depression is well established. Tryptophan (Trp) is an essential amino acid that acts as substrate for serotonin and melatonin biosynthesis, both know to play a role in satiety, anxiety, and depression. Furthermore, low plasma Trp levels have been associated with obesity.Objective: To investigate the effects of Trp supplementation as a conjunctive therapy to conventional life-style intervention on weight lo...

hrp0097p2-223 | Growth and Syndromes | ESPE2023

The Impact of Different Karyotypes on the Response to Growth Hormone Therapy in Girls with Turner Syndrome

El-Hawary Amany , Elsharkawy Ashraf , Gaber Amira , Salem Nanees

Background: Short stature is the most common clinical feature in patients with Turner syndrome (TS). The relation of different karyotyping to growth hormone (GH) level in provocation tests or to the response to GH therapy is debatable.Aim: to study the impact of different karyotypes on the GH level in provocation tests and on the response to GH therapy among a cohort of Egyptian girls with TS.<stro...

hrp0082p1-d3-172 | Growth (2) | ESPE2014

Three-Years Height Outcome During rh-GH Therapy in Subjects with Achondroplasia and Hypochondroplasia

Massart Francesco , Vierucci Francesco , Miccoli Mario , Baggiani Angelo

Background: Achondroplasia (ACH) and hypochondroplasia (HCH) are the most common forms of chondrodysplasia. ACH is characterized by rhizomelic short stature, macrocephaly and lumber lordosis. Because HCH is clinically milder, HCH is often goes unrecognized in childhood but is diagnosed in adult life when disproportionate short stature becomes obvious.Objective: Although episodic reports showed the recombinant human GH (rhGH) treatment may improve short-t...

hrp0097p2-277 | Late Breaking | ESPE2023

Evaluation of body composition and microcirculation in children and adolescents with growth hormone deficiency: effects of replacement therapy.

Rosa Stefano , Ferruzzi Alessandro , Zoller Thomas , Antoniazzi Franco , Pietrobelli Angelo

Aims: The aim of the study is to evaluate body composition and microcirculation in children and adolescents with growth hormone deficiency (GHD) and the effects of replacement therapy. These parameters were also evaluated in children and adolescents with suspected GH deficiency but in whom drug stimulus testing was later found to be normal.Materials and Methods: We examined 44 patients (25 males and 19 females) aged betw...

hrp0095fc6.3 | Sex Development and Gonads | ESPE2022

Gonadal morphology in 46,XY gonadal dysgenesis: I-DSD Registry-based study

Tadokoro-Cuccaro Rieko , Hughes Ieuan , Cools Martine , van de Vijver Koen , Bilharinho de Mendonça Berenice , Domenice Sorahia , L Batista Rafael , Thomazini Dallago Renata , Lisboa Gomes Nathalia , Costa Elaine F. , Maciel-Guerra Andréa T. , Guerra-Junior Gil , Gabriel Ribeiro de Andrade Juliana , Lucas-Herald Angela , Bryce Jillian , Hannema Sabine , Juul Anders , Globa Eugenia , MсElreavey Kenneth , Baronio Federico , Lopez Dacal Jimena , Darendeliler Feyza , Poyrazoglu Sukran , Kolesińska Zofia , Niedziela Marek , Claahsen – van der Grinten Hedi L. , van den Akke Erica L.T. , Herrmann Gloria , Atapattu Navoda , Jain Vandana , Sharma Rajni , Bettendorf Markus , Konrad Daniel , Martin Holterhus Paul , Fica Simona , Skae Mars , Russo Gianni , Rita Stancampiano Marianna , Gazdagh Gabriella , H Davies Justin , Mohamed Zainaba , Nimali Seneviratne Sumudu , Guran Tulay , GÜVEN Ayla , Wasniewska Malgorzata , Mladenov Vilhelm , Verkauskas Gilvydas , Markosyan Renata , Korbonits Marta , Faisal Ahmed S , Hiort Olaf , Wagner Isabel , Thankamony Ajay

Background/Aims: 46,XY gonadal dysgenesis (GD) is classified as complete (CGD) or partial (PGD) depending on gonadal morphology and function. In contrast to the typical female external genitalia in CGD, the phenotype of PGD is variable depending on androgen production. A diagnosis of PGD is based on clinical/biochemical features, gonadal histology and genetic findings. The aim of this study is to characterise these features, particularly histological, in a lar...